Q3 2022 Results

Company overview Financial review 2022 priorities Appendix Financial performance Innovation: Pipeline overview Innovation: Clinical trials Cardiovascular Immunology Neuroscience Oncology iptacopan - CFB inhibitor NCT03955445 (CLNP023B12001B) iptacopan - CFB inhibitor NCT04154787 (CLNP023D12201) Indication Idiopathic membranous nephropathy (IMN) References Abbreviations Other Indication C3 glomerulopathy (C3G) Phase Phase 2 Phase Phase 2 Patients 27 patients from ongoing Ph2 (sample size from Ph3 pending HA discussions Q1 2021), total patients for this study will increase Patients 72 Primary Outcome Measures Arms Intervention Target Patients Characterize the effect of LNP023 treatment on a composite renal response endpoint at 9 months (1. a stable or improved eGFR and, 2. a reduction in proteinuria and 3. an increase in C3 compared to the CLNP023X2202 baseline visit) Open-label LNP023 200mg bid Patients with C3 glomerulopathy Primary Outcome Measures Change from baseline of UPCR derived from 24hr urine collections at Baseline and Week 24 Arms Intervention LNP023 low dose LNP023 high dose Target Patients Read-out Milestone(s) 2025 Read-out Milestone(s) Publication 2023 TBD Publication Wong et al 2021 Nephrology, Dialysis and Transplantation Vol. 36, Suppl. 1: eGFR trajectory Rituximab Patients with biopsy proven iMN who are at high risk of disease progression defined on the basis of antibody anti-PLA2R titre and proteinuria 45 Investor Relations | Q3 2022 Results NOVARTIS | Reimagining Medicine

View entire presentation